Abstract
Common genetic variants of the liver-specific human organic cation transporter 1 (OCT1; SLC22A1) have reduced transport capacity for substrates such as the antidiabetic drug metformin. The effect of the reduced OCT1 function on drug interactions associated with OCT1 has not been investigated and was, therefore, the focus of the study presented here. HEK293 cells expressing human OCT1-reference or the variants R61C, V408M, M420del and G465R were first used to study the kinetics and inhibition pattern of the OCT1 substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+). In the second part OCT1-mediated 14C-metformin uptake was studied in the presence of drugs administered concomitantly with metformin. Transport studies using ASP+ showed that the function of the variants decreased in the following order: OCT1-reference=V408M=M420del >R61C >>G465R. Variants M420del and R61C were more sensitive to drug inhibition, with IC50 values up to 23 times lower than those of the OCT1-reference. Uptake studies using 14C-metformin were in qualitative agreement with those using ASP+, with the exception that a larger reduction in transport capacity was observed for M420del. Concomitantly administered drugs, such as verapamil and amitriptyline, revealed potential drug–drug interactions at clinical plasma concentrations of metformin for OCT1-M420del.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ASP+:
-
4-(4-(dimethylamino)styryl)-N-methylpyridinium
- DDI:
-
drug–drug interaction
- HSA:
-
human serum albumin
- HEK293:
-
human embryonic kidney
- MPP+:
-
1-methyl-4-phenylpyridinium
- OCT:
-
organic cation transporter
- SLC:
-
solute carrier
References
Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM . Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997; 51: 913–921.
Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J . Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333–1340.
Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36: 963–988.
Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008; 51: 5932–5942.
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902–5907.
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.
Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004; 313: 789–793.
Cusi K, Consoli A, DeFronzo RA . Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059–4067.
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379–386.
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997; 16: 871–881.
Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004; 201: 420–428.
Zhang JH, Chung TD, Oldenburg KR . A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67–73.
Scheen AJ . Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359–371.
Edelbroek PM, Zitman FG, Schreuder JN, Rooymans HG, de Wolff FA . Amitriptyline metabolism in relation to antidepressive effect. Clin Pharmacol Ther 1984; 35: 467–473.
Balant L, Fabre J, Zahnd GR . Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 1975; 8: 63–69.
Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D . The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003; 55: 368–374.
Desager JP, Horsmans Y . Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348–371.
McAllister Jr RG, Kirsten EB . The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982; 31: 418–426.
Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S . Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol 2003; 3: 6.
Consortium IHGS . Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931–945.
McTavish D, Sorkin EM . Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989; 38: 19–76.
Neuhoff S, Artursson P, Zamora I, Ungell AL . Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. Pharm Res 2006; 23: 350–359.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y . Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387–412.
Popp C, Gorboulev V, Muller TD, Gorbunov D, Shatskaya N, Koepsell H . Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 2005; 67: 1600–1611.
Pelis RM, Zhang X, Dangprapai Y, Wright SH . Cysteine accessibility in the hydrophilic cleft of human organic cation transporter 2. J Biol Chem 2006; 281: 35272–35280.
Daneshmend TK, Warnock DW, Turner A, Roberts CJ . Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 1981; 8: 299–304.
Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655–660.
Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P . A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 2007; 323: 19–30.
Tucker GT, Houston JB, Huang SM . Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Pharm Res 2001; 18: 1071–1080.
Abshagen U, Besenfleder E, Endele R, Koch K, Neubert B . Kinetics of canrenone after single and multiple doses of spironolactone. Eur J Clin Pharmacol 1979; 16: 255–262.
Cai WM, Zhang YD, Chen B, Cai MH, Luo JP, Ling SS . Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. Acta Pharmacol Sin 2001; 22: 956–960.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9: 242–247.
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G et al. Reduced function SLC22A1 polymorphisms encoding organic cation transporter 1 (OCT1) and glycaemic response to metformin: a Go-DARTS study. Diabetes 2009; 58: 1434–1439.
Otagiri M . A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005; 20: 309–323.
Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H . Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2004; 2: 8.
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y . A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005; 102: 17923–17928.
Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K . Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007; 74: 359–371.
Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I . Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415–422.
Kimura N, Okuda M, Inui K . Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005; 22: 255–259.
Zolk O, Solbach TF, Konig J, Fromm MF . Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 337–348.
Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17: 2127–2135.
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58: 745–749.
Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19: 497–504.
Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009; 9: 127–136.
Sripalakit P, Nermhom P, Maphanta S, Polnok S, Jianmongkol P, Saraphanchotiwitthaya A . Bioequivalence evaluation of two formulations of doxazosin tablet in healthy Thai male volunteers. Drug Der Ind Pharm 2005; 31: 1035–1040.
Acknowledgements
This work was supported by a PhD study grant from AstraZeneca to Gustav Ahlin; the Swedish Research Council (Grant 9478); the Knut and Alice Wallenberg Foundation; the Swedish Fund for Research without Animal Experiments and the Swedish Board of Agriculture.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ahlin, G., Chen, L., Lazorova, L. et al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 11, 400–411 (2011). https://doi.org/10.1038/tpj.2010.54
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2010.54
Keywords
This article is cited by
-
Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
European Journal of Drug Metabolism and Pharmacokinetics (2023)
-
Drug–drug–gene interactions and adverse drug reactions
The Pharmacogenomics Journal (2020)
-
Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype
Pharmaceutical Research (2017)
-
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification
Journal of Cancer Research and Clinical Oncology (2016)
-
Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions
The Pharmacogenomics Journal (2015)